Purpose: To prospectively assess sensitivity and specificity of diffusion indexes of the corpus callosum (CC) for differentiating relapsing neuromyelitis optica (RNMO) from relapsing-remitting multiple sclerosis (RRMS), by using final clinical diagnosis as the reference standard. Materials and Methods: Participants provided informed consent; the study was approved by the institutional review board. Forty-six consecutive patients with RRMS (18 men, 28 women; mean age, 37.7 years; range, 18–58 years) and 26 consecutive patients with RNMO (two men, 24 women; mean age, 38.6 years; range, 19–59 years) underwent diffusion-tensor magnetic resonance imaging.
Background: Neuromyelitis Optica (NMO) is a demyelinating disease of the central nervous system which preferentially involves the optic nerve and the spinal cord. This is the first inflammatory disease of the CNS in which a specific antibody (NMO-IgG) has been detected.
Background: Longitudinally extensive transverse myelitis (LETM) is defined clinically by acute transverse myelitis (ATM) and radiologically by extensive spinal cord (SC) lesions spanning three or more vertebral segments on Magnetic Ressonance Image (MRI). Even that LETM carries a considerable diagnostic challenge, has been regarded as a spectrum of Neuromyelitis optica (NMO). The seropositivity for NMO IgG, a specific biomarker of NMO, is variable in LETM patients around the world and reach 30-35% in brazilian series.
Neuromyelitis optica has not been thoroughly studied in Brazilian patients following the discovery of NMOIgG and its specific antigen aquaporin-4.
OBJECTIVE:To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO). METHODS: This was a chart review and telephone follow-up study of 99 patients with NMO spectrum of disorders (NMOSD) treated with azathioprine (1994-2009). NMOSD were NMO (2006 diagnostic criteria) or partial NMO forms (NMO-immunoglobulin G seropositive)
BACKGROUND: Severe visual loss is seen in both multiple sclerosis-associated optic neuritis (ON) and neuromyelitis optica (NMO)-associated ON.
Background: Neuromyelitis Optica (NMO) and its spectrum disorders (NMOSD), which include recurrent transverse myelitis (rTM) and recurrent optic neuritis (rON) are demyelinating diseases of the central nervous system (CNS).
Background: Using an anti-aquaporin-4 (AQP4) antibody assay discovered in 2005, Japanese patients with neuromyelitis optica (NMO) can easily be differentially diagnosed from those with opticospinal multiple sclerosis (MS).
Background: Based on case series and anecdotal evidence, immunosuppression has been shown to reduce relapse rates and delay disability in Neuromyelitis Optica spectrum disorders (NMOSD) and is currently the mainstay of disease modifying treatment.
Background: Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disorder characterized by recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis(LETM). Lower urinary tract symptoms (LUTS) such as voiding dysfuntion are disturbing in LETM patients and has not been studied in this specific population
OBJECTIVE. Our goal was to describe the spectrum of clinical phenotypes, laboratory and imaging features, and treatment in pediatric patients with neuromyelitis optica.PATIENTS AND METHODS
Sir, We report a 9-yr-old girl with a severe relapsing–remitting course of neuromyelitis optica (NMO) [who had a dramatic and -sustained improvement over a 2-yr period of treatment with mycophenolate mofetil (MMF), the prodrug of mycophenolic acid. A 9-yr-old Caucasian girl, previously healthy, was admitted to A.